Business Wire

OWL-LABS

4.6.2024 15:31:27 CEST | Business Wire | Press release

Share
Owl Labs Launches Meeting Owl® 4+ Camera and AI-Powered Software to Create the First Standalone 360-Degree, Wirelessly Connected Device System for Hybrid Work

Owl Labs, the first company to build AI-powered, 360-degree video conferencing solutions, today launched its next-generation flagship product, the Meeting Owl 4+. It is Owl Labs’ newest all-in-one, 360-degree camera, speaker, and mic device with 4K Ultra HD video for crystal clear video that’s sharper than ever. The new Meeting Owl is powered by the latest Owl Intelligence System (OIS) Software which now allows for wirelessly pairing more devices, so organisations can customise their spaces to meet their evolving needs.

Over 200,000 organisations across nearly 50 countries, from small businesses to 89 companies on the Fortune 100 list to educational institutions, have used Owl Labs products to power millions of hybrid experiences. Owl devices use robotics and proprietary, patented AI-powered software to automatically switch between cameras to capture the best view of in-room attendees, enabling natural, face-to-face conversations that transcend physical distance. With the introduction of the Meeting Owl 4+, Owl Labs now offers enhanced capabilities to more audiences, from small and medium-sized businesses (SMBs) to larger enterprises. In addition to pairing with more devices to cover larger spaces, the Meeting Owl 4+ has several other enterprise-friendly features, including easier fleet management for IT teams and customisable lighting and sound options upon startup.

With the latest AI-powered OIS software, the Meeting Owl 4+ pairs with Owl Labs’ customisable connected device system to capture all angles of the discussion. Owl Labs products can connect with others in over 25 different setup configurations, with both centre-of-room and front-and-centre options. For example, a company can wirelessly connect two Meeting Owls for greater coverage, or a Meeting Owl and an Owl BarTM to ensure all angles are covered, creating a full-room solution. The software is developed in the U.S. by an experienced team of engineers who are continually iterating to make Owl products smarter over time. All software adheres to industry-standard security protocols and Owl devices connect via a private, dedicated wireless network.

This launch is the latest advancement in Owl Labs’ mission to make hybrid meetings more inclusive and collaborative by leveling the playing field between remote and in-room participants. Hundreds of thousands of workplaces have moved beyond traditional conference room setups with equipment permanently mounted to walls and transitioned to user-friendly, plug-and-play Owl products with the flexibility, portability, and affordability that modern distributed offices need. Any type of meeting, in any size room, is covered with Owl Labs’ tailored technology, from sit-down roundtables to stand-up presentations to brainstorms on whiteboards. As companies grow, their video conferencing infrastructure adapts and expands with them. However, a vast market opportunity remains as Owl Labs’ State of Hybrid Work report found only 37% of employers upgraded their video meeting technology in the past year.

“Non-verbal communication is crucial in the workplace for collaboration and rapport, and studies have even shown that non-verbal communication is at least as important as verbal discussion, if not more,” said Frank Weishaupt, CEO of Owl Labs. “As the hybrid workplace has evolved beyond meetings where everyone is in the same room, we need to do away with outdated video technology that doesn't allow remote attendees to clearly see and hear during meetings. Meanwhile, today’s enterprise businesses are evolving their offices and processes faster than ever to keep up with the pace of economic and AI-driven transformation. At Owl Labs, we’re building easy-to-use meeting technology that’s as nimble as they are, from small businesses to the largest enterprises.”

The flexible, plug-and-play Meeting Owl 4+ is enterprise-ready and takes less than six minutes to set up. Features include:

  • Upgraded video quality: The 64-megapixel camera and sensor streams 4K Ultra HD video within a 10-foot radius.
  • Wide-range audio: Powerful, 360-degree speakers and smart mics have an 18-foot pickup radius. Extend the audio range even farther with the new matching, charcoal Expansion Mic.
  • Easy enterprise fleet management: IT administrators can seamlessly manage their fleet of Owl Labs devices from The Nest management tool, including bulk registration, default settings, and more.

The upgraded OIS software includes:

  • Silent Switching: When devices are paired, the technology detects where people are facing even when they’re not speaking, then seamlessly switches to the correct camera with the best view.
  • Quick and easy setup: Pair devices quickly, effortlessly and efficiently.
  • Platform-agnostic: Compatible with Microsoft Teams, Zoom, Google Meet, Slack, and other video conferencing platforms.
  • Improved Front + Centre Experience: Front + Centre experience upgrades introduce more accurate intelligent camera switching whether a participant is actively speaking or silently contributing to ensure the best angle is captured at all times.

The new Meeting Owl 4+ is launching in the United States, Canada and Europe. Customers in the UK can now purchase it for £1,999 / €2,199 (including VAT) through OwlLabs.com, Amazon, or third-party resellers and distribution partners. Find your local reseller or contact sales@owllabs.com.

To see video of the Meeting Owl 4+ in action, purchase other Owl Labs products or ensure your devices have the latest OIS software, visit owllabs.co.uk.

About Owl Labs:

Owl Labs is the first company to build AI-powered, 360-degree video conferencing solutions for hybrid organisations. Its connected device system and Owl Intelligence System™ software make meetings more inclusive and collaborative by leveling the playing field between remote and in-room participants. The Meeting Owl® 4+ is the latest generation of the first WiFi-enabled, 360-degree camera, microphone and speaker that automatically zooms in on whoever’s speaking. Owl Labs has raised £36.8 million in funding and is based in Boston, with remote and hybrid employees all over the world. To learn more and explore the company’s research on the State of Hybrid Work, visit OwlLabs.co.uk.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240531450854/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye